Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing ...

Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for malaria.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into ...

Uliledlimab (TJ004309) is an antibody designed to target CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. I-Mab owns worldwide rights ...

Dazukibart, an anti–interferon beta monoclonal antibody, showed potential in reducing dermatomyositis symptoms, with ...

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...

Monoclonal Antibody to Inhibit IL33 for Autoimmune Disorders is under clinical development by Eli Lilly and Co and currently in Phase I for Autoimmune Disorders.

A recent study has identified a previously unknown antibody target on the Plasmodium falciparum sporozoite surface, providing ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, “Toripalimab has made significant strides in its internationalization. As of today, toripalimab has been approved in 35 countries ...

Stämm unveiled breakthrough results of its continuous bioreactor for monoclonal antibody production with pilot studies in ...